Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the provided transcript. The company recently completed a fundraising round, the proceeds of which are allocated for new product development, team building, marketing, distribution, capex, working capital, and reserves. The funds raised are aimed at accelerating growth in new age businesses while vintage business grows steadily. No indication of plans for raising additional debt or equity in the near term was discussed during the call. Focus is currently on utilizing existing raised funds efficiently towards sustainable growt

Any current/future capex/capital investment/strategic investment?

Fredun Pharmaceuticals plans capex and strategic investments primarily for new product development, team building, marketing, and distribution. Recent fundraising will be used as growth capital to accelerate sustainable growth in new age businesses towards 2029-2030. Planned investments include INR4-5 crores over the next 18-24 months and another INR5-7 crores later for the Wagr e-commerce platform to align and promote sales. The company is expanding manufacturing capacity with a state-of-the-art facility at Palghar and adding contract manufacturing locations to support product portfolio growt

Future growth expectations in sales/revenue/volumes?

Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years. Vintage business expected to grow sustainably at around 15% CAGR for the next 7 to 9 years driven by registrations and existing channels. New age businesses (Pet Care, Nutraceuticals, Mobility) are growing month-on-month with detailed 3 to 7-year plans for each vertical. Wagr e-commerce platform aims for a multi-million dollar monthly revenue in 5 to 7 years. By FY'29, management targets INR 90 crores PAT, with potential for higher performance depending on market conditions. Pe

Future growth expectations in earnings/operating earnings/profits/EPS?

Fredun Pharmaceuticals expects steady, founded growth with no year of de-growth in the past 18 years, aiming to continue this trajectory. Vintage business projected to grow sustainably at ~15% CAGR over the next 7 to 9 years. Management follows a conservative approach, under-promising and aiming to over-deliver on earnings guidance. PAT guidance of INR 90 crores for FY'29 remains intact, with potential to exceed if outcomes are better than expected. New age businesses like Pet Care, Nutra, and Mobility have multi-year plans (3 to 7 years) with expected significant revenue contributions

Current/ Expected Orderbook/ Pending Orders?

Fredun Pharmaceuticals has received an "unbelievable" and "crazy phenomenal" response for their Snacky Jain product. The order book for Snacky Jain has surpassed their initial expectations. Due to high demand, they had to revisit manufacturing and procurement plans. Snacky Jain is expected to be in stores across certain geographies by the end of November 2025. Within the next 6 months, it is planned to be available in most parts of India. They are receiving multiple daily requests for entire stock purchases from customers. Plans to launch more variants of Snacky Jain targeting different nutrit

IN US

Sale is live|00:00:00left today

Fredun Pharmaceuticals LtdQ3 FY25Pharmaceuticals & Biotechnology

Fredun Pharmaceuticals Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,548P/E: 38.3Market Cap: ₹1.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years.
→Vintage business expected to grow sustainably at around 15% CAGR for the next 7 to 9 years driven by registrations and existing channels.
→New age businesses (Pet Care, Nutraceuticals, Mobility) are growing month-on-month with detailed 3 to 7-year plans for each vertical.
→Wagr e-commerce platform aims for a multi-million dollar monthly revenue in 5 to 7 years.
→By FY'29, management targets INR 90 crores PAT, with potential for higher performance depending on market conditions.
→Pet Care division to significantly scale with expansion into 52 countries; strong domestic bases being built to support exports.
→Continual product innovation and new SKUs launch to drive working capital needs and revenue growth.
→Expansion in manufacturing capacity and distribution enhancing scalability and supporting growth across product lines.

Margin guidance

Category 3

→Fredun Pharmaceuticals expects steady, founded growth with no year of de-growth in the past 18 years, aiming to continue this trajectory.
→Vintage business projected to grow sustainably at ~15% CAGR over the next 7 to 9 years.
→Management follows a conservative approach, under-promising and aiming to over-deliver on earnings guidance.
→PAT guidance of INR 90 crores for FY'29 remains intact, with potential to exceed if outcomes are better than expected.
→New age businesses like Pet Care, Nutra, and Mobility have multi-year plans (3 to 7 years) with expected significant revenue contributions.
→EBITDA and net profit showed strong growth in Q2 FY26 (EBITDA +60%, PAT +128%) and H1 FY26 (EBITDA +61%, PAT +96%), indicating operational improvements.
→Long-term vision includes expanding US business to contribute over 51% of revenue by FY 2032.
→Continued investment in new product development, marketing, and team-building to support growth.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No explicit mention of any new fundraising through debt or equity in the provided transcript.
→The company recently completed a fundraising round, the proceeds of which are allocated for new product development, team building, marketing, distribution, capex, working capital, and reserves.
→The funds raised are aimed at accelerating growth in new age businesses while vintage business grows steadily.
→No indication of plans for raising additional debt or equity in the near term was discussed during the call.
→Focus is currently on utilizing existing raised funds efficiently towards sustainable growth and expansion.

Order book

Yes

→Fredun Pharmaceuticals has received an "unbelievable" and "crazy phenomenal" response for their Snacky Jain product.
→The order book for Snacky Jain has surpassed their initial expectations.
→Due to high demand, they had to revisit manufacturing and procurement plans.
→Snacky Jain is expected to be in stores across certain geographies by the end of November 2025.
→Within the next 6 months, it is planned to be available in most parts of India.
→They are receiving multiple daily requests for entire stock purchases from customers.
→Plans to launch more variants of Snacky Jain targeting different nutritional and health needs (gut health, mobility health, geriatric dogs, young dogs) to cater to the demand.

Capex plans

Yes

→Fredun Pharmaceuticals plans capex and strategic investments primarily for new product development, team building, marketing, and distribution.
→Recent fundraising will be used as growth capital to accelerate sustainable growth in new age businesses towards 2029-2030.
→Planned investments include INR4-5 crores over the next 18-24 months and another INR5-7 crores later for the Wagr e-commerce platform to align and promote sales.
→The company is expanding manufacturing capacity with a state-of-the-art facility at Palghar and adding contract manufacturing locations to support product portfolio growth.
→Capex also includes infrastructure to increase production, especially for nutraceuticals, mobility, cosmetics, and pet care products.
→The acquisition of Wagr.ai was a zero-cash cost deal, focusing investment on platform development rather than acquisition price.
→Hiring and building a robust human resource infrastructure across different brands and verticals is a key ongoing strategic investment.

How does Fredun Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Fredun Pharmaceuticals Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Fredun Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio